Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965261736> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W1965261736 endingPage "18" @default.
- W1965261736 startingPage "1" @default.
- W1965261736 abstract "The knowledge of GRPs as molecular chaperones is rapidly evolving. It is anticipated that the GRPs will make special contributions in the areas of basic cell biology, biotechnology, and cancer biology. In particular, they may play a role as the prototype of a class of genes that are regulated by signal transduction pathways originating in the ER and traveling to the nucleus. GRP78 and GRP94 function as molecular chaperones and can bind to malfolded proteins and unassembled complexes. They are induced in response to stress, but once the stress is removed the GRPs are posttranscriptionally modified into biologically inactive forms. The promoters of the grp genes are highly conserved, with several CCAAT-like motifs and GC-rich regions. The high level of redundancy that exists in the mammalian grp promoters may act to ensure that the expression of the genes, both of which are single copy, is unlikely to be significantly lowered in the event of mutation. These genes are thought to be controlled by several transcription factors whose complex interactions with the grp promoters allow variable patterns of grp induction. The promoters of the grp genes constitutively express their gene products, and their promoter activities can be further enhanced in cellular environments of low glucose or oxygen. The grp78 promoter is known to retain its strong activity in differentiated and undifferentiated tissues. These features make it an attractive alternative to viral promoters for use in gene therapy. Gene therapy may also be useful in treating cancer in some cases, especially solid tumors. In these instances, GRP levels are already likely to be quite high. These high levels of GRPs may inhibit the efficacy of several anti-cancer treatments. Suppression of GRP induction, perhaps by anti-sense or ribozyme technology, may prove to be useful in conjunction with anti-cancer drugs to treat tumors." @default.
- W1965261736 created "2016-06-24" @default.
- W1965261736 creator A5017623548 @default.
- W1965261736 creator A5036478028 @default.
- W1965261736 creator A5042328864 @default.
- W1965261736 creator A5067365044 @default.
- W1965261736 creator A5084117210 @default.
- W1965261736 date "1994-01-01" @default.
- W1965261736 modified "2023-09-30" @default.
- W1965261736 title "The Glucose-Regulated Proteins (GRP78 and GRP94): Functions, Gene Regulation, and Applications" @default.
- W1965261736 doi "https://doi.org/10.1615/critreveukargeneexpr.v4.i1.10" @default.
- W1965261736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7987045" @default.
- W1965261736 hasPublicationYear "1994" @default.
- W1965261736 type Work @default.
- W1965261736 sameAs 1965261736 @default.
- W1965261736 citedByCount "366" @default.
- W1965261736 countsByYear W19652617362012 @default.
- W1965261736 countsByYear W19652617362013 @default.
- W1965261736 countsByYear W19652617362014 @default.
- W1965261736 countsByYear W19652617362015 @default.
- W1965261736 countsByYear W19652617362016 @default.
- W1965261736 countsByYear W19652617362017 @default.
- W1965261736 countsByYear W19652617362018 @default.
- W1965261736 countsByYear W19652617362019 @default.
- W1965261736 countsByYear W19652617362020 @default.
- W1965261736 countsByYear W19652617362021 @default.
- W1965261736 countsByYear W19652617362022 @default.
- W1965261736 countsByYear W19652617362023 @default.
- W1965261736 crossrefType "journal-article" @default.
- W1965261736 hasAuthorship W1965261736A5017623548 @default.
- W1965261736 hasAuthorship W1965261736A5036478028 @default.
- W1965261736 hasAuthorship W1965261736A5042328864 @default.
- W1965261736 hasAuthorship W1965261736A5067365044 @default.
- W1965261736 hasAuthorship W1965261736A5084117210 @default.
- W1965261736 hasConcept C101762097 @default.
- W1965261736 hasConcept C104317684 @default.
- W1965261736 hasConcept C138885662 @default.
- W1965261736 hasConcept C150194340 @default.
- W1965261736 hasConcept C179926584 @default.
- W1965261736 hasConcept C41895202 @default.
- W1965261736 hasConcept C54355233 @default.
- W1965261736 hasConcept C86339819 @default.
- W1965261736 hasConcept C86803240 @default.
- W1965261736 hasConcept C95444343 @default.
- W1965261736 hasConceptScore W1965261736C101762097 @default.
- W1965261736 hasConceptScore W1965261736C104317684 @default.
- W1965261736 hasConceptScore W1965261736C138885662 @default.
- W1965261736 hasConceptScore W1965261736C150194340 @default.
- W1965261736 hasConceptScore W1965261736C179926584 @default.
- W1965261736 hasConceptScore W1965261736C41895202 @default.
- W1965261736 hasConceptScore W1965261736C54355233 @default.
- W1965261736 hasConceptScore W1965261736C86339819 @default.
- W1965261736 hasConceptScore W1965261736C86803240 @default.
- W1965261736 hasConceptScore W1965261736C95444343 @default.
- W1965261736 hasIssue "1" @default.
- W1965261736 hasLocation W19652617361 @default.
- W1965261736 hasLocation W19652617362 @default.
- W1965261736 hasOpenAccess W1965261736 @default.
- W1965261736 hasPrimaryLocation W19652617361 @default.
- W1965261736 hasRelatedWork W1606260917 @default.
- W1965261736 hasRelatedWork W1818003313 @default.
- W1965261736 hasRelatedWork W1979259620 @default.
- W1965261736 hasRelatedWork W2009966535 @default.
- W1965261736 hasRelatedWork W2034805612 @default.
- W1965261736 hasRelatedWork W2043249063 @default.
- W1965261736 hasRelatedWork W2111182449 @default.
- W1965261736 hasRelatedWork W2147573427 @default.
- W1965261736 hasRelatedWork W2156533439 @default.
- W1965261736 hasRelatedWork W2952178500 @default.
- W1965261736 hasVolume "4" @default.
- W1965261736 isParatext "false" @default.
- W1965261736 isRetracted "false" @default.
- W1965261736 magId "1965261736" @default.
- W1965261736 workType "article" @default.